Scientific Articles

Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial

08 Feb 2022

 

Marcia S Brose, Bruce Robinson, Steven I Sherman, Jolanta Krajewska, Chia-Chi Lin, Fernanda Vaisman, Ana O Hoff, Erika Hitre, Daniel W Bowles, Jorge Hernando, Leonardo Faoro, Kamalika Banerjee, Jennifer W Oliver, Bhumsuk Keam, Jaume Capdevila

The Lancet Oncology, 2021 Aug

Abstract link

 

 

 

 

 

 

 

Copyright © 2021 Elsevier Ltd. All rights reserved.

Forse può anche interessarti

Privacy Overview
AIOM

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

Analytics

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.